The recent spate of pharmaceutical industry mergers and acquisitions in the USA is aimed at collecting market share, and is evidence of the necessity of scale to leverage pricing and costs, according to Barbara Ryan and Mara Goldstein of US stockbroker Alex Brown & Sons.
There have been no unfriendly acquisitions in the drug segment, they say, although there was rivalry for Sterling Drug between Hoffmann-La Roche and Kodak in 1986, with the latter winning (although recently selling out its prescription medicine drug business to its Sterling Winthrop alliance partner Sanofi Marketletter June 27 and having plans to divest the over-the-counter business as well).
Interestingly, they add, "despite the carnage in drug stock valuations over the past two years, deals have recently begun to surface at much the same multiples as those deals done in the mid-to-late 1990s," about 2.0-2.5 times revenues and around 20 times earnings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze